Peter,
How old is this policy? I keep hearing that the law changed last year. The Ameritrade reference Michael cited hasn't been updated since '99. Then again, the one I cited is also of that vintage. As Michael has been showing, there are IPOs in the pipeline, including MitoKor. BLUE HP would have loved to short SGEN and NWBT as hedges; by the time the 30 days were up, the opportunity was gone. It'll be interesting to see if DOVP can bounce before that period is up. Might be worth an experimental paper short.
In the under $5 department, there's NEOT, with its hypy history, wacky financing, and even wackier results in Parkinson's. They clearly are at sea regarding mechanism of action here, and I agree with "Scott" that it's too early in our understanding of neurotrophins to expect any success in that area. Of course, I'm a little late there; but I at least managed to follow it for a couple of years without buying it.
Cheers, Tuck |
